Sunday, March 30, 2008

Former Zyprexa Sales Rep Spills the Beans

Watch a video of this former Zyprexa sales rep here:
Boston Globe
Ex-drug salesman: We lured docs with gifts
March 30, 2008
By Christine McConville

We all want to think that our doctors prescribe pain pills for our aching backs because it’s what we need, and not because a charming ex-cheerleader turned drug company sales rep has invited him to a Red Sox game.

But, according to a former drug salesman, that second scenario may be closer to the truth.

“We were the beautiful people,” Shahram Ahari, a former Eli Lilly “drug detailer,” told a group of Boston University medical students last week. 
Former Eli Lilly ‘drug detailer’ Shahram Ahari speaks before a group of BU medical students last week.
He said that pharmaceutical companies’ aggressive marketing creates conflicts of interest and increases drug costs.
Ahari, who spent two years promoting drugs such as Prozac and Zyprexa, is telling the medical students what to watch out for when the sales reps come calling.

He is working with The Prescription Project, a group fighting the impact of pharmaceutical marketing on physicians’ prescription decisions.

The group contends that aggressive marketing to physicians by pharmaceutical companies creates conflicts of interest in the medical profession and raises questions about the appropriateness of treatment choices.

Many blame drug companies’ aggressive marketing efforts for a portion of the rise in health-care costs, because physicians are swayed into prescribing newer, more expensive medicines instead of older, less expensive brands.

To push their products, Ahari said, drug companies hire former models, cheerleaders and athletes to promote the new drugs to doctors.

His co-workers, he said, “were all beautiful, vivacious and fun,” but none of them had more than a high-school level science education.

Still, each day, they’d visit scores of medical offices, armed with gifts for the doctors, their staff and their family members, and samples of the drugs they were pushing.

When they weren’t treating the entire office to lunch, or handing out free tickets to sporting events, they’d wine and dine the doctors.

Ahari said he was allowed to spend $60,000 a year on meals.

Eli Lilly spokeswoman Judy Moore disputed Ahari’s account, saying that the company’s sales reps provide a “value-added resource for physicians.”

Ahari said most physicians think they are too smart to be influenced, but drug companies have learned otherwise from experience.

After a drug manufacturer took a group of physicians to an all-expenses-paid conference in the Caribbean, those same physicians began prescribing that drug in earnest.

“Physicians can be influenced like everyone else,” Ahari said. “We paid for that conference with all the prescriptions that came in the next month.”

Moore countered that Lilly’s sales reps help very busy physicians learn more about the cutting-edge products.

“Our reps know the products inside and out. They are professional, passionate and hard-working,” she said.

Here in Massachusetts, the state Senate has just rolled out its plan to contain the growth in health-care costs. The plan calls for an outright ban on pharmaceutical marketing gifts.

If approved, Massachusetts will be the first state to prohibit pharmaceutical sales reps from offering gifts and will ban physicians, their family and staff from accepting them. The bill also calls for uniform, electronic medical records and other cost-saving measures.    

Friday, March 28, 2008

U.S. Justice Dept. Pops Antipsychotic Drug Maker - Promoting Use for Children

Abilify, Geodon, Risperdal, Seroquel and Zyprexa  are the names of the "atypical antipsychotics".  They are newer, more expensive and just as damaging as the older "antipsychotics" such as Thorazine and Haldol.
It is illegal for a drug company to promote a drug for uses not approved by the FDA.    Example.  Promoting Antipsychotic Drugs for "ADHD" .
Otsuka to Pay Fine to Resolve Abilify Marketing Probe
Bloomberg News

By Robert Schmidt and Beth Jinks
March 27, 2008

Otsuka Pharmaceutical Co. agreed to pay $4 million to resolve U.S. allegations it marketed the schizophrenia drug Abilify for off-label uses in cahoots with Bristol-Myers Squibb Co., which settled in September.

The Justice Department accused New York-based Bristol-Myers and Otsuka American Pharmaceutical Inc., a U.S. subsidiary of the closely held Japanese drugmaker which invented Abilify, of promoting the antipsychotic for use in children, and as a remedy for dementia, without regulator approval.

Use in children wasn’t approved by the U.S. Food and Drug Administration at the time, and the drug is required to carry the most severe safety warning, a so-called black box, for use in dementia-related psychosis.

Abilify Booth at NAMI CONVENTION (National Alliance on Mental Illness), San Diego, CA June 20 - June 24, 2007 (courtesy of

In September, Bristol-Myers completed an agreement to pay $515 million to settle U.S. allegations it overcharged the government for drugs and promoted medicines including Abilify for unapproved uses. Bristol-Myers directed its sales force to visit child psychiatrists and nursing homes, the Justice Department said in September. Otsuka’s sales force was “led primarily by Bristol-Myers sales managers,” the department said today.

Otsuka will pay the U.S. government about $2.3 million and the remainder to states’ Medicaid programs, the company said in a statement. It agreed to a corporate integrity agreement, without specifying the length of the compliance and monitoring pledged.

Bristol-Myers also agreed to a five-year corporate integrity agreement that requires the company to maintain compliance programs to monitor business practices. It avoided criminal charges.

The U.S. investigation of Bristol-Myers involved more than 50 medicines. The company was accused of inflating prices used by the government to set reimbursement rates for some drugs, and improper promotional activities for others.   

Vermont spent millions on suspect drug Zyprexa

The Times Argus
Vermont spent millions on suspect drug Zyprexa

March 28, 2008
By Daniel Barlow

MONTPELIER – As the lawsuits against Eli Lilly over its top-selling anti-schizophrenia drug Zyprexa began piling up in 2006, Vermont's state-run insurance program spent nearly $4 million on the drug, according to documents.

That amount may seem like a drop in the bucket when compared to Zyprexa's 2007 sales of $4.8 billion in the United States, but the payments through Vermont's Medicaid program came at a time when 10 states and upwards of 30,000 people were suing the company over the drug.

Launched in 1996, Zyprexa has become the top-selling medication for drug-maker Eli Lilly. But those sales are dropping as lawsuits and leaked corporate documents reveal a decade-long effort to downplay the side effects, including weight gain and an increased chance of diabetes, in the company's promotion of the drug.

Just this week the state of Alaska, population 670,000, settled its lawsuit against Eli Lilly for $15 million over what it claimed were increased Medicaid costs due to health problems associated with taking Zyprexa. That was the first state to settle with the company in the lawsuits.

Vermont is not one of the states now suing Eli Lilly. But on Thursday, the Vermont Association for Mental Health, a Montpelier-based advocacy organization, urged the state to pursue that legal option. Executive Director Ken Libertoff said this case was a "sad commentary" on the influence of the pharmaceutical industry.

While it may not be suing Eli Lilly, Vermont is investigating how the company marketed its drug to doctors and others here, according to Julie Brill, Vermont's assistant attorney general. She said the state subpoenaed marketing materials and internal company documents detailing its marketing plan in January 2007.

Brill said that inquiry is still on-going and she was mum on further details. She said she did not know when more informa-tion on their investigation could be made available to the public.

"We do have an ongoing consumer protection investigation," she said.

More here:

Friday, March 21, 2008

North Dakota - Medicaid Reviews Antipsychotics

Minot Daily News  (North Dakota) 
Medicaid reviews drug spending on mental health

March 21, 2008

North Dakota’s Medicaid program has begun a two-year study of a class of medicines that has raised concerns in several other states.

However, the state’s review of prescribing patterns for atypical anti-psychotics is focused on the high cost of the medicines rather than the prescription controversies that exist elsewhere.

Ten state Medicaid programs, including one in Montana, have filed lawsuits against drug maker Eli Lilly, alleging the company illegally promoted Zyprexa, an atypical anti-psychotic. The first case went to trial in Alaska this month.

Eli Lilly has been under federal investigation since 2004 for its methods of marketing Zyprexa to doctors for treating mild bipolar disorder and dementia in elderly patients. Use in elderly patients has been linked to deaths.

Brendan Joyce, pharmacist with North Dakota Medicaid, said attorneys in a class action case have notified the state that some North Dakota patients are included in a lawsuit against Eli Lilly. Should defendants win an award, the Medicaid program would share a portion as reimbursement of its prescription costs. 


Wednesday, March 19, 2008

Antipsychotics getting POUNDED


March 18, 2008

State board puts Grand Forks psychiatrist on probation for over-prescribing psychotropic meds to 2 children

Grand Forks Herald

A Grand Forks psychiatrist who is CEO and medical director of the Richard P. Stadter Center cannot prescribe psychotropic medications to children after the North Dakota State Board of Medical examiners found he over-prescribed doses to two children under the age of 12.

The stipulation to Dr. Thomas M. Peterson’s license was made during the board’s regular meeting Friday in Bismarck.

Stadter Center’s Peterson can no longer prescribe medications to children under the age of 18, at least until he’s able to complete a prescribing course that deals specifically with how to dose children, the board ruled.

“Peterson was found to have prescribed excessive amounts of atypical antipsychotic medications to two children under his care,” according to the board.

Atypical antipsychotic medications include Risperdal, Zyprexa, Geodon and Seroquel, according to the board.

The board found, and Peterson agreed, that he’d prescribed to one child “such an excessive amount of atypical antipsychotic medications (that) are beyond the acceptable stan-dards of prescriptive practice for a child in this age group,” and for the other child gave a prescription of a “particular combination of medications” that was “injudicious and an ex-cessive use of atypical antipsychotics.”

Peterson’s license will remain on probation for three years. He may apply for reinstatement of an unrestricted license once he completes the ordered course and “if he satisfactorily demonstrates to the Board his ability to renew his practice of prescribing psychotropic medications to children and adolescents,” according to the board.

Friday, March 14, 2008

State suspends area psychiatrist

State suspends area psychiatrist

License yanked after incident at UMMC


State medical regulators last week suspended the license of a local psychiatrist, who practiced at UMass Memorial Medical Center and at a private practice in Westboro, after the doctor allegedly ignored an on-call assignment last spring and then assaulted two hospital police officers and a nursing supervisor later that day.

Dr. Perveen Rathore, 51, of 5 Arrowhead Lane, Westboro, voluntarily agreed not to practice medicine in early June 2007, shortly after the fracas at UMass Memorial. The state Board of Registration in Medicine yanked her medical license March 5, according to state records.

The board’s order alleges Dr. Rathore was the on-call psychiatrist for UMass Memorial on Sunday, May 20, but refused to come in to evaluate an uncooperative patient because she was at a party at the time.

When she showed up at the hospital later that day — after another psychiatrist had been summoned to do the competency evaluation — Dr. Rathore refused to leave the building and grew increasingly belligerent, according to the order. A nursing supervisor called hospital police when she found Dr. Rathore typing an e-mail in the building after being told to leave several times.

“Two UMass police officers approached the respondent and instructed her to leave the hospital, but the respondent ignored them and kept typing,” the order states. “One of the police officers reached over to shut off the computer monitor, and the respondent struck him.”

When the officers moved to arrest Dr. Rathore, she screamed and fought with them and also struck the nursing supervisor, according to the order.

Wednesday, March 12, 2008





March 9, 2008 -- Alarmed at the growing use of psychiatric drugs for children, a key New York lawmaker wants to set up regional centers to advise pediatricians on treating kids' mental and emotional problems.

State Sen. Thomas Morahan (R-Rockland County) will present a bill to the Mental Health Committee Wednesday to create at least three child-psychiatry centers where doctors statewide can call for consultations on troubled kids.

Under the plan, teams consisting of a psychiatrist, a social worker and a "care coordinator" would discuss the child's problem, make referrals and provide other support services to the family.

Based on a pioneering program in Massachusetts, the New York plan is aimed at helping troubled children who may be suffering untreated, and at choosing safe treatments.

Morahan said he acted in response to an investigative report in The Post last month that New York's Medicaid program paid nearly $90 million in 2006 for two dozen psychiatric drugs for kids. The state says that covered 55,700 children 18 and under.

More kids in New York and nationwide are taking powerful anti-psychotics and antidepressants - while most have not been tested adequately on kids or approved by the Food and Drug Administration for their use. Doctors may prescribe them to children or teens "off-label."

Morahan blasted the FDA policy. "They permit these drugs to be prescribed, regardless what the label says," said spokesman Ron Levine. "Many pediatricians may not be aware of the ramifications of psychotropic drugs on the market."

Some of the drugs cause severe - and dangerous - side effects, including Parkinson's-like movement disorders, weight gain, breast growth in boys, and suicidal tendencies. Experts warn that some kids may be misdiagnosed or overmedicated to control behavior problems.

State Health Department officials told The Post they do not require a diagnosis when paying for the drugs.

Tuesday, March 11, 2008

Connecticut joins states suing over Zyprexa

 regarding Seroquel  - Pennsylvania, South Carolina

Boston Globe
Connecticut joins states suing over Zyprexa

March 11, 2008

Hartford, Connecticut Skyline

Connecticut is joining at least nine other states suing drug maker Eli Lilly and Co. over the antipsychotic drug Zyprexa.

Attorney General Richard Blumenthal says Connecticut's lawsuit seeks to recover more than $190 million that that state's medical assistance program spent on Zyprexa over more than a decade.

The lawsuit accuses Indianapolis-based Eli Lilly of running an illegal marketing campaign to promote Zyprexa for unapproved off-label uses, including treating children.

Blumenthal says the campaign also concealed risks associated with the drug, including diabetes, weight gain and cardiovascular problems.

A court in Alaska is currently hearing that state's lawsuit, and eight other states have sued as well.

A message seeking comment has been left with Eli Lilly.


Monday, March 10, 2008

People with dementia getting drugged rather than helped - Reliance on antipsychotics, especially at nursing homes, is under fire.

Star Tribune
People with dementia getting drugged rather than helped - Reliance on antipsychotics, especially at nursing homes, is under fire.
March 9, 2008

It's hard to believe when you meet the vibrant 94-year-old Meta Miller today. But then her daughter Carol Johnson begins describing just how bad it got as she struggled to manage her mom's dementia at home for seven weeks before Thanksgiving in 2006.

"She would roam the house all night with her cane, talking to imaginary people, knocking things down, yelling at me, accusing me of horrible things -- my own mom," Johnson recalled with tears. "And it just got worse when she went to the first nursing home. That's when she started screaming."

To cope, thousands of nursing homes nationwide are doing what a hospice program and then a nursing home did for Miller: using powerful antipsychotic drugs to quiet disruptive people with dementia -- at times a step that's easier and cheaper than taking staff time to fix the problem.

The practice is alarming Medicaid officials. Last year, they ordered state nursing home inspectors to crack down on it.

Of the state's 398 nursing homes, 38 percent were cited last year for using such medications inappropriately, up from 27 percent in 2006.

So dangerous are the drugs that the Food and Drug Administration requires some to carry a "black box warning" that they heighten risk of death for older patients, a warning that it might extend to all antipsychotic drugs. They also increase the risk of confusion and falling.

The drugs often are prescribed whether the resident is psychotic or not.

Obviously, Psychiatry is under a very serious attack - "Shrink Control"

Columbia Daily Tribune
Guns don’t kill people; psychiatry does
By CHARLEY REESE (Former Orlando Sentinel columnist Charley Reese writes for King Features Syndicate.)
March 8, 2008
In view of the rash of shootings recently, may I suggest that what the United States needs is not gun control, but shrink control. When you trace the cause of most of these shootings, it is inevitably mental-health problems in the shooter, and all too often, the shooter is receiving or has received treatment.

There are almost as many theories of psychiatry and psychology as there are practitioners. Which theories work? Which don’t? Nobody seems interested in finding out, lest someone’s lucrative income be lost.

More here:

School shooter stories are being compiled here:


Saturday, March 08, 2008

Ex-FDA official blasts Eli Lilly in court - Expert witness says profits came first

Anchorage Daily News
Ex-FDA official blasts Eli Lilly in court
ZYPREXA SUIT: Expert witness for the state says profits came first.

March 8th, 2008

A retired medical officer with the federal Food and Drug Administration testified Friday that drug maker Eli Lilly distorted the science and downplayed the health risks of its schizophrenia drug Zyprexa to make more money.

John Gueriguian, who worked 20 years for the FDA and is now a consultant, was on the stand in Anchorage Superior Court all day Friday as an expert witness for the state of Alaska.

The state is suing Eli Lilly and Co. to recover costs to its Medicaid system for what it contends are serious health problems, including weight gain and diabetes, caused by Zyprexa.

The state says the company failed to warn of troubles because it counted on Zyprexa to become its next big moneymaker.

Global sales of Zyprexa approached $4.8 billion last year.

At the FDA, Gueriguian worked for the division that oversaw diabetic drugs, not psychiatric medication, so he wasn't directly involved in oversight of Zyprexa. Lawyers working for the state hired him to analyze Lilly documents and e-mails and said it's impossible to get current FDA employees to testify.

If Lilly could show that diabetes was common for this class of drugs, then it would no longer be a special problem for Zyprexa, said a Nov. 28, 2001, company document.

Was it comparable? Tommy Fibich, a Houston attorney representing the state, asked.

Just the opposite, Gueriguian answered.

Zyprexa caused many more such problems than most similar drugs, he said.

"Simply put, it's putting profit over the concern of the consumer," Gueriguian told the jury.

In a 2001 guide for sales representatives, the directive from on high was clear, he said. "Our goal and focus is on creating a market with Donna. The competition wins if we are distracted into talking about diabetes," the guide said.

"Donna" was code for an effort to pitch the drug as treatment for depression and mood changes, Gueriguian said.

Lilly lawyers didn't get to cross-examine Gueriguian on Friday. After court broke for the day, Lilly attorney John Brenner told reporters the company turned over its data to the FDA, which approved the drug in 1996. Zyprexa remains on the market in the United States and more than 80 other countries.

"We didn't hide anything," Brenner said. Regarding Zyprexa, he said, "there's an ongoing debate being played out in the medical community."

Some tidbits presented on Friday came from a string of internal Lilly e-mails generated in 2000. Employees were talking about a meeting with consultants.

One Lilly employee wrote that the consultants were concerned how the company handled the issue of whether Zyprexa leads to diabetes.

"I do believe they made a very strong point that unless we come clean on this, it could get much more serious than we might anticipate," Thomas Brodie wrote in a Oct. 9, 2000, e-mail to others at Lilly.

The next day, another Lilly employee responded that the real concern seemed to be about weight gain, and that the consultants wanted the company to "aggressively face the issue" and work with doctors to help them manage patients' weight. Even if just 2 percent of patients on Zyprexa gained a possible 90 pounds, that amounted to 100,000 people, the employee wrote. "100,000 people putting on 90 pounds of weight is a lot."

Marni Lemons, a Lilly spokeswoman, said Friday that the state's lawyers are focusing on a few misleading or poorly worded documents out of 19 million pages of records.

One thing the jurors didn't learn: Gueriguian was one of the FDA medical officers who fiercely fought approval of the diabetes drug Rezulin, made by Warner-Lambert. It got on the market anyway only to be withdrawn after dozens of deaths and reports of liver toxicity.

Fibich tried to ask Gueriguian questions about Rezulin, but Lilly lawyers objected and he wasn't allowed to.

The trial resumes Monday.


Monday, March 03, 2008

Antipsychotics used to Knock Out Grandma and Grandpa

Comments can be made here:

Low Risk Patients - Heavy Drugs
State's Nursing Homes Might Be Overusing Antipsychotics

March 2, 2008

Connecticut's nursing homes dole out antipsychotic drugs to residents who do not have psychotic disorders at one of the highest rates in the country, raising questions about whether the medications are being used to subdue agitated patients because of a lack of staffing and attention to alternate treatments.

Federal data from the Centers for Medicare & Medicaid Services show that since 2005, Connecticut has consistently ranked in the top four states in the prevalence of antipsychotic drugs dispensed to nursing home residents who have no psychotic or related conditions. In the most recent quarterly report, through September 2007, only Louisiana had a higher prevalence rate than Connecticut, where more than 26 percent of residents who lacked an appropriate psychiatric diagnosis were prescribed antipsychotics.

Nationally, the prevalence rate is 19.8 percent, with several states, such as Florida, Pennsylvania and New Jersey, well below that average.

"This is not a good indicator" for Connecticut, said Charlene Harrington, an expert on nursing home quality and professor of sociology and nursing at the University of California-San Francisco. "One of the main factors [for a high medication rate] is not having enough staff. If patients are having behavioral problems, it's easier to give them a pill to keep them quiet" than to hire more staff. "It's cheaper. They'll sleep a lot."

Nursing-home staffing is now a focus of state lawmakers, who are weighing proposals that would update the state's minimum staffing standards to nationally recommended levels. The existing standards are more than 25 years old and rank among the least stringent in the country. The staffing proposals were prompted by a series in The Courant that detailed the troubled patient-care and financial history of one of the state's largest chains, Haven Healthcare, which filed for bankruptcy after the stories appeared.

Federal data from the past three years show that Connecticut has ranked highest or second-highest among states in the prevalence of antipsychotic use among "low-risk" nursing home residents, defined as those who do not exhibit cognitive impairment and behavioral problems. In the most recent reporting period, 23.3 percent of low-risk residents were receiving antipsychotics, compared with the national average of 16.5 percent.

Among "high-risk" residents who do exhibit those problems, Connecticut prescribes antipsychotics at the highest rate in the country — 55.2 percent, compared with the national average of 42.5 percent, according to data from the most recent reporting period.

More here:

Florida Nabs New Jersey Psychiatrist

A retired New Jersey psychiatrist was arrested Friday and charged with writing prescriptions for friends though he is not licensed in Florida. Richard Feinsod, 65, of Lake Worth was booked into the Palm Beach County Jail. He was licensed to practice medicine in New Jersey from 1975 until he retired 2003. An anonymous tipster led the sheriff's office and state Department of Health to investigate him, police said

Saturday, March 01, 2008

Psychiatry as punishment

URGENT Mothers Act: Watch videos and take action

There are two videos about "The Mother's Act" (S. 1375, also proposed as H.R. 20), a federal bill that is dangerous to mothers and their newborns but being promoted under the guise of ensuring that “new mothers and their families are educated about postpartum depression, screened for symptoms, and provided with essential services….”  This is quite simply, false, and the video shows exactly the effect this bill will have; it will push more mothers onto dangerous antidepressant drugs documented by the U.S. FDA to cause mania, psychosis, hallucinations, suicidal ideation and in some cases, homicidal ideation (as with the antidepressant Effexor).  There is no language in the bill requiring full disclosure of the drug risks to mothers prescribed psychotropic drugs, (the most common "treatment" for mothers diagnosed with post partum depression), no language requiring mothers be given options for non-harmful treatments and real medical care other than drugs. So please watch the videos, take action and above all — pass this email on to everyone you know.

 1) Watch one mother's story of what happened to her when she was "helped" by the same type of psychiatric intervention that this bill proposes:

 2) Watch her newscast gathering support:

Then take action

1) Sign onto the petition against the Mothers Act here:

2) The bill is currently in the Senate Health, Education, Labor and Pensions (HELP) Committee as S. 1375.   It is now scheduled for a vote on March 5th so calls and faxes are needed NOW. You can follow the simple instructions below.

(If you fax, you can use the same letter and simply add the Senator's name to the top of the fax, sending each Senator his own fax.)

Whether you call or fax, keep your message simple:

You are opposed because of the damage that will be done to mothers and infants due to the treatment that will result from the legislation. There is no language in the bill warning that the psychotropic drugs prescribed for "depression" can cause damage to both mother and child and that this is a complete violation of informed consent.

Use your own words... keep it brief, mention the bill number — S. 1375.

Call/Fax list:


Sen. Michael B. Enzi (WY)
Tele: 202-224-3424
Fax: 202-228-0359

Sen. Judd Gregg (NH)
Tele: 202-224-3324
Fax: 202-224-4952

Sen. Lamar Alexander (TN)
Tele: 202-224-4944
Fax: 202-228-3398

Sen. Richard Burr (NC)
Tele: 202-224-3154
Fax: 202-228-2981

Sen. Johnny Isakson (GA)
Tele: 202-224-3643
Fax: 202-228-0724

Sen. Lisa Murkowski (AK)
Tele: 202-224-6665
Fax: 202-224-5301

Sen. Orrin G. Hatch (UT)
Tele: 202-224-5251
Fax: 202-224-6331

Sen. Pat Roberts (KS)
Tele: 202-224-4774
Fax: 202-224-3514

Sen. Wayne Allard (CO)
Tele: 202-224-5941
Fax: 202-224-6471

Sen. Tom Coburn (OK)
Tele: 202-224-5754
Fax: 202-224-6008

Democrats by Rank

Edward Kennedy (MA)
Tele: 202-224-4543
Fax: 202-224-2417

Christopher Dodd (CT) - a co-sponsor of the bill.
Tele: 202-224-2823
Fax: 202-224-1083

Tom Harkin (IA)
Tele: 202-224-3254
Fax: 202-224-9369

Barbara Mikulski (MD)
Tele: 202-224-4654
Fax: 202-224-8858

Jeff Bingaman (NM)
Tele: 202-224-5521
Fax: 202-224-2852

Patty Murray (WA)
Tele: 202-224-2621
Fax: 202-224-0238

Jack Reed (RI)
Tele: 202-224-4642
Fax: 202-224-4680

Hillary Rodham Clinton (NY)
Tele: 202-224-4451
Fax: 202-228-0282

Barack Obama (IL) - a co-sponsor of the bill
Tele: 202-224-2854
Fax: 202-228-4260

Bernard Sanders (VT) - a co-sponsor of the bill
Tele: 202-224-5141
Fax: 202-228-0776

Sherrod Brown (OH) - a co-sponsor of the bill
Tele: 202-224-2315
Fax: 202-228-6321